Pharmos (PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Clarksterh who wrote (1329)	12/1/2004 9:07:35 PM
From: Clarksterh	Read Replies (1) of 1386

One possibility, but it seems non-credible, is that as you know mGCS is more diagnostic than the other components and they have added an enrollment criteria that says that to get in as a GCS 7 or 8 your mGCS has to be <5 I think the answer to my own question is that Pharmos did indeed find a way to admit only the sicker GCS 7 and 8 patients. I believe they changed the criteria for CT - the score required remained the same but in the Ph II the entrance criteria were any >=2 except one type of very superficial injury (epidural haematoma?), but in the Ph III the entrance criteria were changed to be >=2 with visible parenchimal(sp?) damage (and/or Subarachnoid Hemmorage - Pharmos isn't entirely clear on this or maybe I don't understand the terms well enough). Anyone remember any of the details about this change in entrance criteria? Clark

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next